Search Results

Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for central nervous system disorders, today announced the initiation of patient dosing with GM-1020 in a Phase 2a study in Major Depressive Disorder (MDD) to assess safety, tolerability, and efficacy.

Avidity Biosciences, Inc. announced positive initial AOC 1020 data from the Phase 1/2 FORTITUDE™ trial demonstrating unprecedented and consistent reductions of greater than 50% in DUX4 regulated genes, trends of functional improvement, and favorable safety and tolerability in people living with facioscapulohumeral muscular dystrophy.

Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials for GM-1020, the only novel oral, small-molecule NMDA receptor channel blocker currently in clinical development.

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Harbour BioMed announced that the first patient has been dosed in its ongoing phase I trial of the first-in-class anti-B7H7 antibody HBM1020 in the United States.

Panavance Therapeutics Inc. announced that Greg Bosch, Chairman and CEO of Panavance Therapeutics will present at BioNJ’s Thirteenth Annual BioPartnering Conference on Tuesday, April 18, 2023 at 10:20 AM ET in Somerset, NJ.